Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western PopulationRODIG, Scott J; MINO-KENUDSON, Mari; JANNE, Pasi A et al.Clinical cancer research (Print). 2009, Vol 15, Num 16, pp 5216-5223, issn 1078-0432, 8 p.Article

EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung CancerKOIVUNEN, Jussi P; MERMEL, Craig; LEE, Jinseon et al.Clinical cancer research. 2008, Vol 14, Num 13, pp 4275-4283, issn 1078-0432, 9 p.Article

A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase InhibitorsSASAKI, Takaaki; KOIVUNEN, Jussi; CAPELLETTI, Marzia et al.Cancer research (Chicago, Ill.). 2011, Vol 71, Num 18, pp 6051-6060, issn 0008-5472, 10 p.Article

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingENGELMAN, Jeffrey A; ZEJNULLAHU, Kreshnik; KOSAKA, Takayuki et al.Science (Washington, D.C.). 2007, Vol 316, Num 5827, pp 1039-1043, issn 0036-8075, 5 p.Article

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutationsMUKOHARA, Toru; ENGELMAN, Jeffrey A; TENEN, Daniel G et al.Journal of the National Cancer Institute. 2005, Vol 97, Num 16, pp 1185-1194, issn 0027-8874, 10 p.Article

Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wildtype CancersYONESAKA, Kimio; ZEJNULLAHU, Kreshnik; LINDEMAN, Neal et al.Clinical cancer research (Print). 2008, Vol 14, Num 21, pp 6963-6973, issn 1078-0432, 11 p.Article

Characterizing the cancer genome in lung adenocarcinomaWEIR, Barbara A; WOO, Michele S; SHAH, Kinjal et al.Nature (London). 2007, Vol 450, Num 7171, pp 893-898, issn 0028-0836, 6 p.Article

EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapyPAEZ, J. Guillermo; JÄNNE, Pasi A; NAOKI, Katsuhiko et al.Science (Washington, D.C.). 2004, Vol 304, Num 5676, pp 1497-1500, issn 0036-8075, 4 p.Article

A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard ImmunohistochemistryMINO-KENUDSON, Mari; CHIRIEAC, Lucian R; RODIG, Scott J et al.Clinical cancer research (Print). 2010, Vol 16, Num 5, pp 1561-1571, issn 1078-0432, 11 p.Article

A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screeningJÄNNE, Pasi A; BORRAS, Ana M; DISTEL, Robert J et al.Clinical cancer research. 2006, Vol 12, Num 3, pp 751-758, issn 1078-0432, 8 p., 1Article

Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinibJACKMAN, David M; HOLMES, Alison J; LINDEMAN, Neal et al.Journal of clinical oncology. 2006, Vol 24, Num 27, pp 4517-4520, issn 0732-183X, 4 p.Article

EGFR Mutations Are Detected Comparably in Cytologic and Surgical Pathology Specimens of Nonsmall Cell Lung CancerSMOUSE, Jason H; CIBAS, Edmund S; JÄNNE, Pasi A et al.Cancer. 2009, Vol 117, Num 1, pp 67-72, issn 0008-543X, 6 p.Article

Intravascular cytotoxic T-cell lymphoma : A case report and review of the literatureGLEASON, Briana C; BRINSTER, Nooshin K; GRANTER, Scott R et al.Journal of the American Academy of Dermatology. 2008, Vol 58, Num 2, pp 290-294, issn 0190-9622, 5 p.Article

EGFR Mutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Carcinoma Than FISH, CISH, and ImmunohistochemistrySHOLL, Lynette M; YUN XIAO; JOSHI, Victoria et al.American journal of clinical pathology. 2010, Vol 133, Num 6, pp 922-934, issn 0002-9173, 13 p.Article

The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non-Small Cell Lung Cancer with EGFR MutationsHEON, Stephanie; YEAP, Beow Y; LINDEMAN, Neal I et al.Clinical cancer research (Print). 2012, Vol 18, Num 16, pp 4406-4414, issn 1078-0432, 9 p.Article

No Evidence for Interference of H&E Staining in DNA Testing: Usefulness of DNA Extraction From H&E-Stained Archival Tissue SectionsMORIKAWA, Teppei; SHIMA, Kaori; LINDEMAN, Neal I et al.American journal of clinical pathology. 2012, Vol 138, Num 1, pp 122-129, issn 0002-9173, 8 p.Article

Phase ii clinical trial of chemotherapy-naive patients ≥ 70 years of age treated with erlotinib for advanced non-small-cell lung cancerJACKMAN, David M; YEAP, Beow Y; FREIDLIN, Boris et al.Journal of clinical oncology. 2007, Vol 25, Num 7, pp 760-766, issn 0732-183X, 7 p.Article

Epidermal growth factor receptor mutation testing in the care of lung cancer patientsSEQUIST, Lecia V; JOSHI, Victoria A; VERLANDER, Peter et al.Clinical cancer research. 2006, Vol 12, Num 14, issn 1078-0432, 4403s-4408s, 2Conference Paper

LKB1 modulates lung cancer differentiation and metastasisHONGBIN JI; RAMSEY, Matthew R; LIANG, Mei-Chih et al.Nature (London). 2007, Vol 448, Num 7155, pp 807-810, issn 0028-0836, 4 p.Article